SOURCE: Gene Express, Inc.

March 10, 2008 11:08 ET

Gene Express Becomes Member of The Personalized Medicine Coalition

TOLEDO, OH--(Marketwire - March 10, 2008) - Gene Express, Inc. today announced that the Company has become a member of The Personalized Medicine Coalition (PMC). PMC membership encompasses a broad spectrum of academic, industrial, patient and healthcare provider constituencies.

Membership is open, but not limited, to universities and academic medical centers, non-profit research entities, relevant trade associations, patient advocacy groups, government officials (ex-officio), healthcare organizations, healthcare providers, payers, information technology companies and research-based commercial companies that offer an array of products and services including research tools, diagnostic technologies and products, screening services and therapeutic interventions.

David S. Lester, Ph.D., Senior Vice President of Strategy and Corporate Development of Gene Express, has been selected to join PMC's Public Policy Committee which is chaired by Robert Wells, HealthFutures, LLC. This committee governs, under a set of rules previously established by the PMC Board, the adoption of all of the organization's public policy positions, and oversees the strategies by which they are communicated to target audiences, including all branches of the federal government as well as other non-governmental agencies.

Dr. Lester stated, "We are honored to join the PMC. This demonstrates Gene Express's commitment to its mission to accelerate the integration of molecular diagnostics into personalized medicine. As a member of the PMC's Public Policy Committee, I look forward to sharing my research interests and using my experience in public science policy activities to further the efforts of the group."

To learn more about PMC, please go to

About The Personalized Medicine Coalition (PMC)

The Personalized Medicine Coalition (PMC) is an independent, non-profit group that works to advance the understanding and adoption of personalized medicine for the ultimate benefit of patients. Our diverse members work together to educate opinion leaders and the public about the issues that will shape how personalized medicine develops -- and how quickly all of us can benefit from it.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information